Compare CRK & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRK | NUVL |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.8B |
| IPO Year | 1995 | 2021 |
| Metric | CRK | NUVL |
|---|---|---|
| Price | $21.03 | $102.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | $22.30 | ★ $134.13 |
| AVG Volume (30 Days) | ★ 2.0M | 455.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 288.16 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $555,231,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.48 | $1,165.56 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | ★ 32.11 | N/A |
| 52 Week Low | $14.65 | $55.54 |
| 52 Week High | $31.17 | $113.02 |
| Indicator | CRK | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 57.62 |
| Support Level | $20.35 | $101.37 |
| Resistance Level | $22.07 | $107.13 |
| Average True Range (ATR) | 1.25 | 3.44 |
| MACD | 0.13 | 0.38 |
| Stochastic Oscillator | 38.26 | 90.59 |
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.